425.453.0404

US FDA Approved Trials For Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Alkermes ALKS 7290-201: A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

NCT07755410

Study Evaluation Process

  • Screening: Determine eligibility and safety through medical examinations, questionnaires, and interviews.
  • Informed Consent: Receive detailed information about the trial, including risks and benefits.
  • Treatment: Receive investigational medication and placebo, and follow the trail protocol regarding current treatments and medications.
  • Monitoring: Close monitoring of conditions and side effects through check-ups, laboratory tests, EKG’s and assessments.

NWCRC in Bellevue, WA. Research and medical studies patient lounge.

CONTACT US

To be contacted about this study, fill out the contact form or call 425-453-0404.

This field is for validation purposes and should be left unchanged.
We complete all visits in person. Do you live within 50 miles of Bellevue, WA?(Required)


Are you interested in participating in clinical trials?(Required)


Please indicated which study you are interested in.(Required)